Vaxart Inc., in collaboration with researchers from multiple academic institutions, evaluated the VXA-G1.1-NN vaccine against ...

Vaxart (NASDAQ:VXRT) shares rose in post market trading on Wednesday after the company said it met its main goals in ...

Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart’s second-generation norovirus vaccine candidate ...

Vaxart (NASDAQ:VXRT) shares rose in post-market trading on Wednesday after the company announced the publication of complete data from a Phase 2 trial for its oral pill norovirus vaccine candidate ...

$159.5 million of cash, cash equivalents and marketable securities as of March 31, 2025 The company is exploring the potential for continued development of its norovirus vaccine candidates ...

Covid vaccine manufacturer Moderna has completed a new site in the UK, which it says will help prepare the the country ...

Actively screening for the 10,000 participant portion of COVID-19 Phase 2b trial; Dosing expected to begin in second quarter of 2025 Completed enrollment of Phase 1 clinical trial evaluating Company’s ...

Vaxart Inc (VXRT) reports significant revenue growth and clinical advancements, despite facing operational hurdles and NASDAQ ...